Founded in 2018, Lingke Pharma (凌科药业) focuses on discovery and development of FIC/BIC therapies in autoimmune disease, inflammation and oncology. Its core programs center on second-generation highly selective and third-generation tissue-specific JAK inhibitors, with the small-molecule JAK1 candidate LNK01001 reporting positive Phase II data in rheumatoid arthritis, atopic dermatitis and ankylosing spondylitis showing strong efficacy and favorable safety. Multiple programs (including LNK01002 and LNK01003) have reported encouraging early clinical data, LNK01004 has enrolled its first patient in an Ib study for psoriasis and atopic dermatitis, and several assets are preparing to transition into Phase III. The company has submitted multiple end-of-Phase II / pre-Phase III meeting applications and says it will scale clinical development and invest in R&D teams and technology platforms. Frost & Sullivan is cited forecasting the JAK1 inhibitor market could reach USD 30.5 billion by 2030, underscoring the large market opportunity. Lingke says its innovation and clinical execution are being validated while it progresses toward broader late-stage development and eventual commercialization. Lynk Pharmaceuticals is a Hangzhou-based clinical-stage company focused on developing small-molecule FIC and BIC drugs for oncology and autoimmune diseases. Led by Dr. Zhao-Kui (ZK) Wan, Chairman and CEO, the core team has deep expertise in medicinal chemistry, biology, clinical and commercial development, with an average of more than 20 years in drug R&D. The company emphasizes innovation and differentiation, concentrating on highly selective second-generation and tissue-restricted third-generation JAK inhibitors while exploring novel targets. It currently has four Phase II clinical trials across four indications with promising clinical data. A few programs are expected to enter Phase III in the near future, and additional pipeline candidates have shown promising clinical and preclinical data with potential to become BIC/FIC drugs for several indications. The company intends to use the funds to accelerate the clinical development of its core products. Lynk Pharmaceuticals is a Hangzhou-based drug R&D company founded in 2018 and led by Chairman and CEO Dr. Zhao-Kui (ZK) Wan. It focuses on development of global FIC/BIC small-molecule drugs targeting autoimmune diseases, inflammation and cancers. In three and a half years since its establishment Lynk has obtained IND approvals for three original products in China and the United States and launched global clinical development. The company completed an ex-China out-license of LNK01001 and in-licensed a first-in-class RAS program from Kobe University and RIKEN in 2020. Lynk recently closed a $50M Series B to fund Phase I and II clinical trials for multiple programs and to support preclinical development of new projects. Management also plans to use proceeds to expand international business and strengthen collaborations with partner companies.

Total raised

$122M

Funding rounds

3

Latest round

Series C

Latest activity

Sep 2023